TY - JOUR
T1 - Niemann-pick C disease gene mutations and age-related neurodegenerative disorders
AU - Zech, Michael
AU - Nübling, Georg
AU - Castrop, Florian
AU - Jochim, Angela
AU - Schulte, Eva C.
AU - Mollenhauer, Brit
AU - Lichtner, Peter
AU - Peters, Annette
AU - Gieger, Christian
AU - Marquardt, Thorsten
AU - Vanier, Marie T.
AU - Latour, Philippe
AU - Klünemann, Hans
AU - Trenkwalder, Claudia
AU - Diehl-Schmid, Janine
AU - Perneczky, Robert
AU - Meitinger, Thomas
AU - Oexle, Konrad
AU - Haslinger, Bernhard
AU - Lorenzl, Stefan
AU - Winkelmann, Juliane
N1 - Funding Information:
MZ has received travel expenses form Actelion Pharmaceuticals Ltd. FC has received funding for travel from Medtronic. AJ has received funding for travel from Allergan and Ipsen Pharmaceuticals. BM received travel compensation from Novartis and Boehringer-Ingelheim, lecturing fees from Orion and Glaxo-Smith-Kline, grant support from GE Healthcare, Boehringer-Ingelheim, Desitin, TEVA-Pharma, and serves as a consultant to Bayer-Schering Pharma and the Michael J. Fox Foundation for Parkinson's Disease Research. MV has received travel expenses, carried out paid and unpaid consultancy work, and presentation honoraria from Actelion Pharmaceuticals Ltd., and has received travel expenses, presentation honoraria, and been invited to meetings funded and organized by Genzyme Corporation and Shire HGT. PLa has received presentation honoraria from Actelion Pharmaceuticals France. HK has received travel expenses, carried out paid consultancy work, and received presentation honoraria from Actelion Pharmaceuticals Ltd. CT serves on scientific advisory boards for Boehringer Ingelheim and UCB, has received speaker honoraria from Boehringer Ingelheim, UCB, and Mundipharma as well as travel compensation from UCB, Boehringer-Ingelheim, and Mundipharma. TMei was supported by the German Network for Mitochondrial Disorders (mitoNET 01GM0867), the European Commission Seventh Framework Program (N. 261123), Genetic European Variation in Disease Consortium, and German Ministry for Education and Research (01GR0804-4). BH serves on a scientific advisory board for Merz Pharmaceuticals; has received funding for travel from Biogen Idec, Ipsen, and Merz Pharmaceuticals; has received speaker honoraria from Allergan and Ipsen, and receives research support from Ipsen and the DFG. SL received grants from UCB Pharma, TEVA, Boehringer, Grünenthal, Orion. JW serves on a scientific advisory board for UCB; has received speaker honoraria from UCB and Boehringer Ingelheim; has filed a patent re: Winkelmann et al. Nat Genet 2007; and receives research support from the German RLS foundation, the Deutsche Forschungsgemeinschaft (DFG) and the Fritz Thyssen Foundation. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
PY - 2013/12/30
Y1 - 2013/12/30
N2 - Niemann-Pick type C (NPC) disease is a rare autosomal-recessively inherited lysosomal storage disorder caused by mutations in NPC1 (95%) or NPC2. Given the highly variable phenotype, diagnosis is challenging and particularly late-onset forms with predominantly neuropsychiatric presentations are likely underdiagnosed. Pathophysiologically, genetic alterations compromising the endosomal/lysosomal system are linked with age-related neurodegenerative disorders. We sought to examine a possible association of rare sequence variants in NPC1 and NPC2 with Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD) and progressive supranuclear palsy (PSP), and to genetically determine the proportion of potentially misdiagnosed NPC patients in these neurodegenerative conditions. By means of high-resolution melting, we screened the coding regions of NPC1 and NPC2 for rare genetic variation in a homogenous German sample of patients clinically diagnosed with PD (n = 563), FTLD (n = 133) and PSP (n = 94), and 846 population-based controls. The frequencies of rare sequence variants in NPC1/ 2 did not differ significantly between patients and controls. Disease-associated NPC1/2 mutations were found in six PD patients (1.1%) and seven control subjects (0.8%), but not in FTLD or PSP. All rare variation was detected in the heterozygous state and no compound heterozygotes were observed. Our data do not support the hypothesis that rare NPC1/2 variants confer susceptibility for PD, FTLD, or PSP in the German population. Misdiagnosed NPC patients were not present in our samples. However, further assessment of NPC disease genes in age-related neurodegeneration is warranted.
AB - Niemann-Pick type C (NPC) disease is a rare autosomal-recessively inherited lysosomal storage disorder caused by mutations in NPC1 (95%) or NPC2. Given the highly variable phenotype, diagnosis is challenging and particularly late-onset forms with predominantly neuropsychiatric presentations are likely underdiagnosed. Pathophysiologically, genetic alterations compromising the endosomal/lysosomal system are linked with age-related neurodegenerative disorders. We sought to examine a possible association of rare sequence variants in NPC1 and NPC2 with Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD) and progressive supranuclear palsy (PSP), and to genetically determine the proportion of potentially misdiagnosed NPC patients in these neurodegenerative conditions. By means of high-resolution melting, we screened the coding regions of NPC1 and NPC2 for rare genetic variation in a homogenous German sample of patients clinically diagnosed with PD (n = 563), FTLD (n = 133) and PSP (n = 94), and 846 population-based controls. The frequencies of rare sequence variants in NPC1/ 2 did not differ significantly between patients and controls. Disease-associated NPC1/2 mutations were found in six PD patients (1.1%) and seven control subjects (0.8%), but not in FTLD or PSP. All rare variation was detected in the heterozygous state and no compound heterozygotes were observed. Our data do not support the hypothesis that rare NPC1/2 variants confer susceptibility for PD, FTLD, or PSP in the German population. Misdiagnosed NPC patients were not present in our samples. However, further assessment of NPC disease genes in age-related neurodegeneration is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84893673648&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0082879
DO - 10.1371/journal.pone.0082879
M3 - Article
C2 - 24386122
AN - SCOPUS:84893673648
SN - 1932-6203
VL - 8
JO - PLoS ONE
JF - PLoS ONE
IS - 12
M1 - e82879
ER -